Privium Fund Management B.V. Sells 14,142 Shares of Pfizer Inc. (NYSE:PFE)

Privium Fund Management B.V. lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 39.2% during the third quarter, Holdings Channel.com reports. The institutional investor owned 21,978 shares of the biopharmaceutical company’s stock after selling 14,142 shares during the quarter. Privium Fund Management B.V.’s holdings in Pfizer were worth $636,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Olistico Wealth LLC acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Pfizer in the second quarter valued at $29,000. Quarry LP bought a new position in shares of Pfizer in the second quarter valued at about $31,000. Financial Connections Group Inc. acquired a new stake in shares of Pfizer during the 2nd quarter worth about $34,000. Finally, ESL Trust Services LLC bought a new stake in shares of Pfizer during the 1st quarter worth about $37,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on PFE shares. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Citigroup began coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 target price for the company. Finally, Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Eight analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Trading Down 1.2 %

NYSE:PFE opened at $26.72 on Friday. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $31.54. The firm’s fifty day moving average is $28.89 and its 200-day moving average is $28.63. The firm has a market cap of $151.42 billion, a P/E ratio of 36.11, a P/E/G ratio of 0.87 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the previous year, the business earned ($0.17) EPS. The firm’s revenue was up 31.2% compared to the same quarter last year. Equities analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.29%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Insider Activity

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.